PRI Insider (Volume 4, Issue 12) March 29
In This Issue: On March 26th, the Supreme Court began hearing oral arguments for the case that will decide the future of the abortion pill. Since the pandemic, the FDA has loosened restrictions on the abortion drugs mifepristone and misoprostol. According to one expert, “The telehealth policy, which the FDA temporarily implemented during the COVID-19 pandemic before making it permanent, is really ‘what opened the gate’ to the drug’s broader use.” This has directly contributed to the uptick in abortions. Last year, the total number of abortions in the U.S. surpassed 1 million for the first time in over a decade.